Skip to main content

Table 2 Response of neoadjuvant chemotherapy and surgery resection rate in the two groups (N = 248)

From: Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis

 

XELOX group

(N = 159)

DOS group

(N = 89)

P

Response evaluation

  

0.823

 CR

2 (1.2)

1 (1.1)

 

 PR

53 (33.3)

33 (37.0)

 

 SD

87 (54.7)

46 (51.6)

 

 PD

14 (8.9)

9 (10.3)

 

 Not assessable

3* (1.9)

0 (0)

 

 RR (CR plus PR)

55 (34.5)

34 (38.1)

0.569

 DCR (CR plus RR plus SD)

142 (89.2)

80 (89.7)

0.886

Patients received surgery

  

0.4850

 Radical surgery

111 (69.8)

65 (73.0)

 

 Non-radical surgery

48 (30.2)

34 (27.0)

 
  1. *There patients in XELOX group did not have response evaluation because of acute stomach perforation after the first regimen of chemotherapy